Twitter | Search | |
Search Refresh
Abingworth Aug 7
Portfolio News: meets primary endpoint in Phase 2b study of OPT-302 in
Reply Retweet Like
Alfredo Adán Civera Sep 5
Reply Retweet Like
Kathleen Wolf Davis Aug 29
People keep asking what I’m doing for . They seem surprised @ my answer: trying to keep my newly one-eyed father () from driving a tractor post diagnosis. Mom’s on board. So, it’s sort of a weekend with style.
Reply Retweet Like
Fay Moody Sep 21
Very proud that NE CCGs are at the forefront of the fight against exploitative pharma companies. Promoting patient choice and clinical efficiency.
Reply Retweet Like
Notal Vision Mar 13
Too often, patients present with poor VA at diagnosis. We can do better.
Reply Retweet Like
Peter Simcock Sep 21
Great news today. High Court has finally approved for treatment of . I have used this drug very successfully for years for my private patients. This will save millions of £.
Reply Retweet Like
Alfredo Adán Civera Dec 29
Reply Retweet Like
RXi Pharmaceuticals 1 Aug 18
Announces Postive from Phase 1/2 trial with -109 for Scarring
Reply Retweet Like
Clinica London 26 Feb 18
Early signs of the eye disease ? Learn how treatment works and which drugs are used:
Reply Retweet Like
Invitria device 22 May 18
Please have a look at the following article. The author shares his experience of setting up a nurse-led service to deliver anti-VEGF intravitreal injections and how injection assistant devices supported training
Reply Retweet Like
EmpoweredPatient 4 Oct 17
Reply Retweet Like
PennClinNeg May 17
We've noticed an increase in enquiries from patients who have experienced delay in diagnosis and treatment for their . Any delays in relation to this condition could have devastating effects and timely management is absolutely vital
Reply Retweet Like
LifeSci Advisors 9 Oct 17
Dr. Slakter had a great discussion about with Dr. Nieca Goldberg , a replay can be found here:
Reply Retweet Like
REGENXBIO May 13
Our CSO, Dr. Olivier Danos, had a wonderful time presenting at the Inherited Retinal Dystrophies Symposium at UCLA last week. It was a great exchange of knowledge about a disease area we are passionate about.
Reply Retweet Like
Brain Machine Innovations 25 Mar 18
Stem cell therapy for vision loss: Will it work for you?
Reply Retweet Like
touch OPHTHALMOLOGY Nov 21
Reply Retweet Like
Genentech 3 May 18
can cause sudden, blurred vision and vision loss if not detected early. Learn more about symptoms & prevention here
Reply Retweet Like
Novartis 10 Nov 17
⚡ Novartis announces new clinical trial data in age-related macular degeneration
Reply Retweet Like
Santen Inc. Oct 28
Join us this evening for conversation and refreshments at our Scientific Open House. experts will answer questions and discuss our pipeline and clinical trials for , , , and other .
Reply Retweet Like
DDNews Online Aug 20
closes $80M to advance pan-VEGF inhibitor GB-102 into Ph2 vs & To also advance preclinical GB-401 lead into the clinic in 2020
Reply Retweet Like